A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
← catalyst calendarNCT05623020 · readout in 1,521 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,116estimated
Sites
127
Countries
Australia, Austria, Belgium +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-10 | actual | When the study began enrolling |
| Primary completion | 2030-10-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-10-03 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Elranatamab
- Drug: Daratumumab
- Drug: Lenalidomide
- Drug: Dexamethasone
- Drug: Bortezomib
Primary outcomes
what the primary-completion date above is the date OFPart 1 Dose Limiting Toxicity
measured From the first dose of elranatamab/first full dose in combination with EDR until 28 days (+/- visit window) from the first administration of elranatamab with daratumumab and lenalidomide
Part 2: Progression free survival per IMWG
measured From randomization up to 97 months.
Part 2: Minimal Residual Disease negative CR rate
measured At 12 months after randomization
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed